Harvard Medical School: Veritas for Sale (Part I)

Why This Story Keeps Coming Back

HMS isn’t just a medical school. It’s a global signal amplifier. Research published by Harvard-affiliated faculty
is cited, re-cited, taught to trainees, translated into clinical guidelines, and echoed in hospital corridors far
from Boston. When HMS sneezes, medical conferences hand out tissues branded by “educational partners.”

That influence creates a simple, uncomfortable arithmetic: even a small tilt in judgmenttoward a sponsor,
toward a product, toward a narrative of “innovation”can ripple outward. Conflicts of interest (COI) aren’t
merely about bad intentions. They’re about incentives, human psychology, and the quiet power of
“who pays for the coffee.” ^[5]

To be fair, industry relationships also help turn lab discoveries into therapies. Universities don’t run
manufacturing plants. They don’t staff global regulatory teams. They don’t (usually) ship cold-chain biologics
at 2 a.m. Translation costs money, and the private sector is often the vehicle. The question is not whether
collaboration should exist. The question is: who steers, who benefits, and who double-checks the steering?

From Ivory Tower to Venture Pipeline

Translation is expensive, and someone pays

Over the last few decades, elite research universities have built sophisticated commercialization systems:
technology transfer offices, startup accelerators, licensing teams, and legal infrastructure that can turn a
promising molecule into intellectual property (IP) with a future revenue stream.

Harvard’s Office of Technology Development (OTD) is one of the most visible examples of this modeldesigned
to translate university inventions into products “that make the world a better place,” typically through licensing
or startup formation. ^[3] And yes, when those inventions generate royalties, Harvard’s policies describe how
inventors share in that royalty stream. ^[4]

Harvard Magazine has reported that in a five-year span, OTD helped faculty start dozens of companies and raise
significant equity financing, while also noting substantial commercialization revenue and corporate research funding
in a single fiscal year. ^[2] These figures matter, not because revenue is inherently shameful, but because money
changes the temperature of decision-making. When success metrics include “companies launched” and “licenses signed,”
a university can start to feel less like a lighthouse and more like an airportstill useful, but suddenly obsessed
with throughput.

When your lab notebook meets a term sheet

Commercialization creates a new cast of characters in the research story: founders, advisors, investors, boards,
and “strategic partners.” A professor can be simultaneously a scientist, a clinician, a mentor, a grant applicant,
andwithout any cartoonish corruptiona person with equity in a company whose success depends on a certain
interpretation of evidence.

This isn’t a scandal; it’s a structural tension. The same brilliance that produces a breakthrough can also
produce a strong belief that the breakthrough must workand that belief becomes even stickier when it’s
stapled to stock options.

The Conflict-of-Interest Rulebook

What HMS says it’s trying to do

HMS does not pretend COI is a niche issue. Its policy framework openly acknowledges that faculty collaborate with
companies and that these relationships can be essential for translationwhile also emphasizing the need to
identify and mitigate risks to research integrity, teaching, and clinical obligations. ^[1]

Notice the key word: mitigate. Not “ban everything,” not “pretend it’s fine,” but manage the risk.
That approach is common across academic medicine, including guidance and measurement efforts by national
organizations like the Association of American Medical Colleges (AAMC). ^[11]

Revisions, tightening, and the long game

Policies evolve when reality evolvesand when reputations feel heat. Harvard Magazine has described HMS policy
revisions as part of a comprehensive review of academia-industry practices, including restrictions related to
industry-sponsored research and tighter rules in settings involving human subjects. ^[6]

In other words: the rulebook exists, and it gets rewritten as the world changes. That’s good.
But a rulebook is not a substitute for culture. Anyone who has ever been to a faculty meeting knows that the most
powerful force in any institution is not “policy,” it’s “what we all quietly allow because it’s inconvenient to fight.”

The small stuff: gifts, meals, and “educational” vibes

In medicine, the little things are rarely little. The psychological literature (and common sense) says that even
modest perks can create a sense of reciprocityoften unconsciously. That’s why many academic centers moved to
restrict gifts and promotional activities long before “transparency” became fashionable.

Harvard has been publicly linked to broader moves to curb promotional talks and certain categories of personal
gifts, travel, or meals in the context of medical school faculty relationships with drug and device makers. ^[14]
The point isn’t to police lunch. The point is to reduce the risk that lunch becomes a marketing tool wearing a lab coat.

Sunshine, Meet Shadow

Open Payments: when the receipts go public

If you want to understand why “Veritas for Sale” is even a phrase, you have to meet America’s grand transparency
experiment: the Open Payments program.

The Centers for Medicare & Medicaid Services (CMS) describes Open Payments as a national disclosure program
that publishes financial relationships between reporting entities (including drug and device companies) and covered
recipients like physicians. ^[5] The data is publicly accessible, searchable, and updated by program year.
CMS has also published headline totals for recent program yearsnumbers big enough to make a hospital compliance
officer develop a thousand-yard stare. ^[5]

Meanwhile, investigative reporting projects have made the data even more legible. ProPublica’s “Dollars for Docs”
tool, for example, has described legally required disclosures of payments to doctors and teaching hospitals and
offers a searchable interface focused on certain payment categories and time windows. ^[7]
When the public can look up who’s getting paid, the “trust me” era endsand the “explain this” era begins.

Transparency doesn’t automatically equal trust

Here’s the twist: transparency can backfire. Research published in JAMA Network Open has suggested that the
nationwide disclosure environment was associated with decreased trust in physicians, raising concerns about how
patients interpret the existence of financial tieseven when the payments are small. ^[9]
Stanford’s health policy community has also summarized this dynamic as an unintended consequence of public
disclosure systems. ^[10]

This puts institutions like HMS in a tough spot. They must disclose and manage COI to protect integrity, but they
also live in a world where disclosure can look like confessioneven when the relationship was legitimate, governed,
and aimed at bringing a therapy to patients.

When Money Meets Medicine: Where Bias Sneaks In

Bias is not always briberysometimes it’s gravity

Most COI problems are not a suitcase of cash. They’re subtler:

• Study design choices that favor a sponsor’s comparator or endpoint.
• Publication timing that turns “good news” into a press release and “bad news” into a delayed appendix.
• Framing that shifts uncertainty from “we don’t know yet” to “early evidence suggests…”
• Overconfidence born from proximity to a product’s development team.

None of these require villainy. They require incentives and the normal human tendency to see what we hope is true.
That’s why COI policies focus on disclosure, thresholds, review, and managementnot just punishment. ^[1]

CME, speakers, and the education-marketing costume change

Continuing medical education (CME) is where the boundary between learning and persuasion can get blurry.
Historically, industry-funded “education” sometimes behaved like marketing with better fonts.
Academic medicine responded by tightening policies and standards.

A Pew report on best practices for academic medical centers, for instance, has recommended strong disclosure rules
and cautioned against industry-funded speaking engagements directed at trainees, clinicians, or the public. ^[12]
And commentary in the medical literature has described institutions moving to limit or restructure industry support
for CME, including restrictions on promotional talks and certain personal benefits. ^[14]

The practical issue is simple: when a respected Harvard-affiliated name stands in front of a room with slides and
authority, the audience hears more than informationthey hear endorsement. That’s why “speakers bureau”
is such a loaded phrase in medicine: it can turn the prestige of academia into a marketing megaphone.

Students, Patients, and the Awkward Questions

Every COI policy ultimately collides with people who didn’t sign up for the complexity: students and patients.
Students want to learn medicine, not interpret disclosure statements like they’re reading the terms and conditions
of a streaming service. Patients want care, not a scavenger hunt through databases.

Still, the tools exist. Open Payments is searchable. Investigative databases exist. ^{[5] [7]}
Physicians can review and dispute payment data through formal processes described by professional organizations
like the American Medical Association (AMA). ^[13]

And yet, the hardest question remains the most human one:
If my doctor has a financial relationship with a company, can I trust the advice?

The honest answer is unsatisfying: it depends. It depends on the size and nature of the relationship, how it’s
managed, how transparent it is, and whether clinical decisions are insulated from marketing influence.
That’s not a comforting slogan, but it’s closer to truth than pretending the issue is binary.

So… Is Veritas Actually for Sale?

If “truth” were literally for sale, the checkout line would be chaosimagine trying to return a study because it
didn’t fit your hypothesis and the receipt says “store credit only.”

The more realistic worry is this: truth can be rented. Not in a dramatic, criminal way, but through influence:
the gentle reshaping of what gets studied, what gets emphasized, what gets funded, and what gets celebrated.

HMS’s policy language emphasizes collaboration plus safeguardsidentify, disclose, mitigate, protect. ^[1]
That’s the right direction. But the modern biomedical ecosystem is fast, lucrative, and extremely good at turning
“partnership” into “pressure.” Commercialization offices optimize for translation. Companies optimize for market.
Academics optimize for prestige and funding. Everyone can be rationaland the system can still drift.

Part I, then, is the setup: the ecosystem, the incentives, the policies, and the public data.
Part II is where things get sharper: what “management” looks like in practice, where it succeeds, where it fails,
and why the same institution can be both a guardian of evidence and a beneficiary of commercialization.

Conclusion

Harvard Medical School sits at the intersection of discovery and deliverywhere science becomes medicine, and
medicine becomes markets. That intersection is not inherently corrupt. It is inherently complicated.

The smartest takeaway is also the least fun: conflict-of-interest risk is normal in modern academic medicine,
and strong systems are required to keep incentives from rewriting evidence.
Disclosure matters. Management matters more. And culturethe quiet, daily decisions about what’s acceptablematters most.

If Veritas is HMS’s brand promise, then the real question is not whether the promise is false.
It’s whether the institution can keep that promise while operating in a world where truth has competitors,
quarterly targets, and a surprisingly persuasive catered lunch.

Field Notes: Five Scenes from the COI Circus (Experiences)

The topic of “Veritas for Sale” can feel abstract until you picture what it looks like on the ground. The following
scenes are compositescommon patterns reported across academic medicinemeant to capture the lived texture of how
conflicts of interest and commercialization pressures can show up in real life.

1) The Disclosure Slide That Everyone Reads Like It’s a Fire Exit Sign

A lecturer begins with a disclosure slide: consulting fees, advisory roles, research support, maybe a patent.
The audience squints politely, then mentally moves on. Disclosures are necessary, but they’re often treated like
a box-checkimportant in theory, easy to ignore in practice. The uncomfortable truth is that a disclosure doesn’t
neutralize bias; it just announces the possibility of it. The rest depends on how the institution and the speaker
manage the situation, not just how quickly the slide disappears.

2) The “Educational” Dinner with Suspiciously Good Dessert

Someone invites clinicians to a dinner talk. The speaker is credentialed, the slides are clean, and the venue has
the lighting of a romantic comedy. Nothing said is technically false. Yet the selection of studies, the emphasis
on a particular product’s benefits, and the minimized discussion of alternatives quietly point the audience in one
direction. This is how influence works when it’s trying to look professional: it doesn’t shout; it curates.

3) The Lab Meeting Where the Startup Looms in the Background

A promising line of research is moving fast. People are excited. Then a question lands in the room:
“Are we publishing this now, or waiting?” Waiting can mean more data, better validationand sometimes, a more
valuable licensing position. Nobody says “money” out loud. But everyone feels the weight of it. When a scientific
timeline starts sharing a calendar with a business timeline, the lab notebook can become a negotiation.

4) The Patient Who Brings Receipts (Literally)

A patient looks up their doctor on Open Payments and asks about a financial relationship. The clinician isn’t
necessarily guilty of anything. They may have done legitimate consulting, or participated in research, or received
a small meal at a conference. But the patient’s trust question is realand it deserves a real answer. These are
awkward conversations, yet they can also be healthy: they push medicine toward clarity, explanation, and humility.
Transparency is only useful if it can be translated into plain language that patients can understand.

5) The Compliance Officer as the Unofficial Philosopher

Somewhere in the institution, someone is tasked with converting the messy human world into policy categories:
“related financial interest,” “outside activity,” “management plan,” “recusal,” “threshold.” This role can look like
bureaucracy until you realize it’s actually institutional ethics in spreadsheet form. The best compliance cultures
don’t treat COI review like a gotcha game; they treat it like risk engineeringbecause that’s what it is.
The goal isn’t to punish collaboration. The goal is to stop collaboration from quietly steering the science.

These scenes are why “Veritas for Sale” isn’t just a spicy headline. It’s a reminder that modern medicine runs on
relationshipsbetween universities and companies, clinicians and patients, evidence and incentives.
If Part I is the map, these experiences are the weather. And in Part II, we’ll talk about what happens when the
forecast turns.

SEO Tags